ES2769578T3 - Hidantoínas que modulan el procesamiento de APP mediado por BACE - Google Patents

Hidantoínas que modulan el procesamiento de APP mediado por BACE Download PDF

Info

Publication number
ES2769578T3
ES2769578T3 ES14751458T ES14751458T ES2769578T3 ES 2769578 T3 ES2769578 T3 ES 2769578T3 ES 14751458 T ES14751458 T ES 14751458T ES 14751458 T ES14751458 T ES 14751458T ES 2769578 T3 ES2769578 T3 ES 2769578T3
Authority
ES
Spain
Prior art keywords
alzheimer
disease
administration
compound
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14751458T
Other languages
English (en)
Spanish (es)
Inventor
Varghese John
Dale E Bredesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Buck Institute for Research on Aging
Original Assignee
Buck Institute for Research on Aging
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Buck Institute for Research on Aging filed Critical Buck Institute for Research on Aging
Application granted granted Critical
Publication of ES2769578T3 publication Critical patent/ES2769578T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES14751458T 2013-02-12 2014-02-12 Hidantoínas que modulan el procesamiento de APP mediado por BACE Active ES2769578T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361763830P 2013-02-12 2013-02-12
PCT/US2014/016100 WO2014127042A1 (en) 2013-02-12 2014-02-12 Hydantoins that modulate bace-mediated app processing

Publications (1)

Publication Number Publication Date
ES2769578T3 true ES2769578T3 (es) 2020-06-26

Family

ID=51354522

Family Applications (2)

Application Number Title Priority Date Filing Date
ES14751458T Active ES2769578T3 (es) 2013-02-12 2014-02-12 Hidantoínas que modulan el procesamiento de APP mediado por BACE
ES19199279T Active ES2975235T3 (es) 2013-02-12 2014-02-12 Hidantoínas que modulan el procesamiento de APP mediado por BACE

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES19199279T Active ES2975235T3 (es) 2013-02-12 2014-02-12 Hidantoínas que modulan el procesamiento de APP mediado por BACE

Country Status (11)

Country Link
US (6) US20140371283A1 (enExample)
EP (2) EP3653609B1 (enExample)
JP (2) JP6471100B2 (enExample)
KR (2) KR102220259B1 (enExample)
CN (1) CN104995176B (enExample)
AU (1) AU2014216390B2 (enExample)
CA (1) CA2899938C (enExample)
DK (1) DK2956443T3 (enExample)
ES (2) ES2769578T3 (enExample)
IL (1) IL240555B (enExample)
WO (1) WO2014127042A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3653609B1 (en) 2013-02-12 2024-04-03 Buck Institute for Research on Aging Hydantoins that modulate bace-mediated app processing
AU2016220049C1 (en) 2015-02-18 2021-02-25 Buck Institute For Research On Aging Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
JP2018525447A (ja) * 2015-08-27 2018-09-06 ナントネウロ，エルエルシー Ａｐｐ選択的ｂａｃｅ阻害のための組成物およびそのための使用
WO2017096049A1 (en) 2015-12-03 2017-06-08 The University Of North Carolina At Pembroke Materials for cathepsin b enhancement and methods of use
ES2910833T3 (es) * 2016-08-19 2022-05-13 Foresee Pharmaceuticals Co Ltd Composición farmacéutica y procedimientos de usos
US10532102B2 (en) 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
CN107468690B (zh) 2017-08-11 2020-01-31 北京卓凯生物技术有限公司 4-氧-烷基化特特拉姆酸类化合物及其制备方法与应用
CN107353239B (zh) * 2017-08-11 2019-06-18 北京卓凯生物技术有限公司 4-氧-烷基化特特拉姆酸类化合物及其制备方法
WO2019169183A1 (en) * 2018-03-01 2019-09-06 The Regents Of The University Of Califorinia Amyloid protein-selective bace inhibitors (asbis) for alzheimer's disease
CN110652516A (zh) * 2018-06-29 2020-01-07 上海绿谷制药有限公司 甘露糖醛二酸的组合物在治疗帕金森氏症中的应用
EP3890618A4 (en) * 2018-12-04 2023-01-11 The Brain Protection Company PTY Ltd COMBINATIONAL THERAPIES COMPRISING IMPLANTABLE DAMPING DEVICES AND THERAPEUTIC AGENTS FOR TREATING A CONDITION AND SYSTEMS AND METHODS OF USE THEREOF
EP3890619A1 (en) 2018-12-04 2021-10-13 The Brain Protection Company PTY Ltd Combinatorial therapies including implantable damping devices and therapeutic agents for treating a condition and associated systems and methods of use
US11926599B1 (en) 2023-10-23 2024-03-12 King Faisal University 1-(2-chlorobenzylideneamino)-5,5-diphenylimidazolidine-2,4-dione as an antimicrobial compound

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4995971A (enExample) * 1973-01-27 1974-09-11
DE2448869A1 (de) 1973-10-19 1975-09-04 Mcneilab Inc 4-oxo-2-imidazolidinylidenharnstoffe, verfahren zu ihrer herstellung und arzneimittel
US4025517A (en) * 1975-06-23 1977-05-24 Mcneil Laboratories, Incorporated 4-Oxo-2-hexahydropyrimidinylidene ureas
JPS554305A (en) * 1978-06-13 1980-01-12 Nippon Zoki Pharmaceut Co Ltd Remedy for disease caused by stress and its preparation
US5070100A (en) 1983-09-14 1991-12-03 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives
US4864028A (en) * 1983-09-14 1989-09-05 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
CH677886A5 (enExample) 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
JPH06507782A (ja) 1990-06-15 1994-09-08 サイオス　ノバ　インコーポレイテッド アルツハイマー病のアミロイド形成開症状を示すヒト以外の組換え哺乳動物
AU652997B2 (en) 1991-01-21 1994-09-15 Elan Pharmaceuticals, Inc. Test and model for alzheimer's disease
DE69233109T2 (de) 1992-01-07 2004-05-19 Elan Pharmaceuticals, Inc., San Francisco Transgene tiermodelle fur alzheimer-krankheit
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
AU702293B2 (en) 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
FR2730932B1 (fr) 1995-02-27 1997-04-04 Oreal Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie
JPH11507538A (ja) 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
FR2742676B1 (fr) 1995-12-21 1998-02-06 Oreal Nanoemulsion transparente a base de tensioactifs silicones et utilisation en cosmetique ou en dermopharmacie
FR2755854B1 (fr) 1996-11-15 1998-12-24 Oreal Nanoemulsion a base de lipides amphiphiles non-ioniques et cationiques et utilisations
FR2760970B1 (fr) 1997-03-18 2000-03-10 Oreal Nanoemulsions a base de lipides amphiphiles non-ioniques et de silicones aminees et utilisations
AU5002399A (en) 1998-07-17 2000-02-07 National Broach And Machine Company Full form roll finishing technique
ES2318902T3 (es) 1998-09-24 2009-05-01 PHARMACIA & UPJOHN COMPANY LLC Secretasa en la enfermedad del alzheimer.
FR2787027B1 (fr) 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters gras de sucre ou d'ethers gras de sucre et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787026B1 (fr) 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters mixtes d'acide gras ou d'alcool gras, d'acide carboxylique et de glyceryle, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787326B1 (fr) 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787325B1 (fr) 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de sorbitan oxyethylenes ou non oxyethylenes, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787728B1 (fr) 1998-12-23 2001-01-26 Oreal Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2787703B1 (fr) 1998-12-29 2001-01-26 Oreal Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788007B1 (fr) 1999-01-05 2001-02-09 Oreal Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788449B1 (fr) 1999-01-14 2001-02-16 Oreal Nanoemulsion a base de citrates d'alkylether, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2789076B1 (fr) 1999-02-02 2001-03-02 Synthelabo Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique
US7161962B1 (en) 1999-05-27 2007-01-09 Nuera Communications, Inc. Method and apparatus for coding modem signals for transmission over voice networks
FR2811564B1 (fr) 2000-07-13 2002-12-27 Oreal Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
WO2002055562A2 (en) 2001-01-11 2002-07-18 Eastman Chem Co Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
FR2819427B1 (fr) 2001-01-18 2003-04-11 Oreal Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
EP2545937A1 (en) 2001-06-05 2013-01-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
US7476393B2 (en) 2002-11-29 2009-01-13 L'oreal Process for the preparation of a cationic nanoemulsion, and cosmetic composition
CA2534950A1 (en) 2003-08-08 2005-02-24 Schering Corporation Cyclic amine bace-1 inhibitors having a benzamide substituent
CN1863770B (zh) 2003-08-08 2011-05-25 先灵公司 具有杂环取代基的环胺base-1抑制剂
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
CA2548388A1 (en) 2003-12-15 2005-06-30 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7468402B2 (en) 2004-03-17 2008-12-23 Baker Hughes Incorporated Polymeric nanoemulsion as drag reducer for multiphase flow
CA2561532A1 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Methods for detecting substances which bind to the amyloid precursor protein or beta amyloid fragments, and binding compounds
US7618978B2 (en) 2004-04-22 2009-11-17 Eli Lilly And Company Amides as BACE inhibitors
IL162288A0 (en) 2004-06-01 2005-11-20 Future Products Man S A Compositions and methods for treating neurodegenerative disorders
CA2579724A1 (en) 2004-06-16 2006-01-26 Wyeth Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
CA2578600A1 (en) 2004-06-16 2006-01-26 Wyeth Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase
JP2008507538A (ja) 2004-07-22 2008-03-13 シェーリング　コーポレイション 置換アミドβセクレターゼインヒビター
CA2575340A1 (en) 2004-07-28 2006-02-09 Schering Corporation Macrocyclic beta-secretase inhibitors
PE20060692A1 (es) 2004-09-21 2006-07-19 Lilly Co Eli Inhibidores bace
GB0500683D0 (en) 2005-01-13 2005-02-23 Novartis Ag Organic compounds
BRPI0606636A2 (pt) 2005-01-13 2009-07-07 Novartis Ag compostos macrocìclicos úteis como inibidores de bace
ATE482214T1 (de) 2005-06-14 2010-10-15 Schering Corp Aspartylproteasehemmer
US8722708B2 (en) 2005-06-14 2014-05-13 Merck Sharp & Dohme Inc. Substituted isoindolines as aspartyl protease inhibitors
EP1896406A2 (en) 2005-06-14 2008-03-12 Shering Corporation The preparation and use of compounds as protease inhibitors
WO2006138264A2 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
US7759353B2 (en) 2005-06-14 2010-07-20 Schering Corporation Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods of treatment
ATE489370T1 (de) 2005-06-14 2010-12-15 Schering Corp Herstellung und verwendung von verbindungen als aspartylproteasehemmer
CA2609562A1 (en) 2005-06-14 2006-12-28 Schering Corporation Macrocyclic heterocyclic aspartyl protease inhibitors
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
BRPI0613578A2 (pt) * 2005-06-30 2012-01-17 Wyeth Corp composito da fórmula i; uso de um composto de fórmula i; e composição farmacêutica
TW200730523A (en) 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
RU2008106936A (ru) 2005-09-26 2009-11-10 Вайет (Us) Соединения амино-5-[4-(дифторметокси)фенил]-5-фенилимидазолона для ингибирования бета-секретазы
CN101296926A (zh) 2005-10-27 2008-10-29 先灵公司 天冬氨酰蛋白酶抑制剂
CN101351460A (zh) 2005-10-31 2009-01-21 先灵公司 天冬氨酰蛋白酶抑制剂
CN101360716A (zh) * 2005-11-21 2009-02-04 阿斯利康(瑞典)有限公司 新颖的2-氨基-咪唑-4-酮化合物及其在制备用于治疗认知缺损、阿尔茨海默病、神经变性和痴呆的药物中的用途
GB0602951D0 (en) 2006-02-14 2006-03-29 Novartis Ag Organic Compounds
JP2009532464A (ja) 2006-04-05 2009-09-10 アストラゼネカ・アクチエボラーグ ２−アミノピリミジン−４−オン及びＡβ−関連の病理を治療又は予防するためのその使用
GB0611064D0 (en) 2006-06-05 2006-07-12 Novartis Ag Organic compounds
CA2653650A1 (en) 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
TW200815449A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds II
TW200815443A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds I
TW200808796A (en) 2006-06-14 2008-02-16 Astrazeneca Ab New compounds III
TW200815447A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds IV
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
KR20090041387A (ko) 2006-07-20 2009-04-28 노파르티스 아게 마크로시클릭 락탐
CA2657280A1 (en) 2006-07-20 2008-01-24 Novartis Ag Macrocyclic compounds useful as bace inhibitors
EP2094645A1 (en) 2006-11-23 2009-09-02 Novartis AG 2-hydroxy-1,3-diaminopropane derivatives
CN101631779A (zh) 2006-12-12 2010-01-20 先灵公司 含有三环系统的天冬氨酰蛋白酶抑制剂
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
TW200831091A (en) * 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
JP2010521457A (ja) * 2007-03-12 2010-06-24 メルク・シャープ・エンド・ドーム・コーポレイション 単環式アニリドスピロラクタムｃｇｒｐ受容体アンタゴニスト
CL2008000784A1 (es) 2007-03-20 2008-05-30 Wyeth Corp Compuestos amino-5-[-4-(diflourometoxi) fenil sustituido]-5-fenilmidazolona, inhibidores de b-secretasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar alzheimer, deterioro cognitivo, sindrome de down, disminucion co
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
US20090041201A1 (en) 2007-08-06 2009-02-12 Carestream Health, Inc. Alignment apparatus for imaging system
BRPI0815673A2 (pt) 2007-08-23 2015-02-18 Novartis Ag Sulfonas cíclicas substituídas por aminobenzila úteis como inibidores de bace.
US20090062361A1 (en) 2007-08-30 2009-03-05 Allergan, Inc. Therapeutic hydantoins
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
JP2011527311A (ja) 2008-07-10 2011-10-27 ノバルティス アーゲー Ｂａｃｅ阻害薬として有用なアミノベンジル置換環状スルホン誘導体
WO2010047372A1 (ja) 2008-10-22 2010-04-29 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２－アミノピリミジン－４－オンおよび２－アミノピリジン誘導体
AP2011005707A0 (en) 2008-11-11 2011-06-30 Cspc Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd Inclusion complexes of pinocembrin with cyclodextrin or its derivatives.
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
WO2011044187A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
MX353096B (es) 2010-08-19 2017-12-19 Buck Institute For Age Res Star Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
US20120165346A1 (en) 2010-12-22 2012-06-28 Astrazeneca Ab Compounds and their use as BACE inhibitors
US8877744B2 (en) 2011-04-04 2014-11-04 Hoffmann-La Roche Inc. 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors
EP3653609B1 (en) 2013-02-12 2024-04-03 Buck Institute for Research on Aging Hydantoins that modulate bace-mediated app processing
JP2018525447A (ja) * 2015-08-27 2018-09-06 ナントネウロ，エルエルシー Ａｐｐ選択的ｂａｃｅ阻害のための組成物およびそのための使用

Also Published As

Publication number Publication date
US10766867B2 (en) 2020-09-08
CN104995176B (zh) 2019-02-22
JP6471100B2 (ja) 2019-02-13
KR102220259B1 (ko) 2021-02-25
US11091444B2 (en) 2021-08-17
EP3653609A1 (en) 2020-05-20
KR102051485B1 (ko) 2019-12-03
AU2014216390A1 (en) 2015-07-30
JP2016507575A (ja) 2016-03-10
AU2014216390B2 (en) 2018-05-10
US20140371283A1 (en) 2014-12-18
KR20150115808A (ko) 2015-10-14
ES2975235T3 (es) 2024-07-04
WO2014127042A1 (en) 2014-08-21
EP2956443A1 (en) 2015-12-23
EP2956443A4 (en) 2016-09-07
US10202355B2 (en) 2019-02-12
US20200148648A1 (en) 2020-05-14
US20160009658A1 (en) 2016-01-14
US9926280B2 (en) 2018-03-27
EP2956443B1 (en) 2019-09-25
EP3653609C0 (en) 2024-04-03
JP6773820B2 (ja) 2020-10-21
US20160159746A1 (en) 2016-06-09
US20180194737A1 (en) 2018-07-12
CA2899938C (en) 2021-10-19
IL240555A0 (en) 2015-10-29
CN104995176A (zh) 2015-10-21
EP3653609B1 (en) 2024-04-03
KR20190134839A (ko) 2019-12-04
DK2956443T3 (da) 2020-01-20
JP2019056012A (ja) 2019-04-11
IL240555B (en) 2019-02-28
US20200017449A1 (en) 2020-01-16
CA2899938A1 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
ES2975235T3 (es) Hidantoínas que modulan el procesamiento de APP mediado por BACE
US10835546B2 (en) App specific BACE inhibitors (ASBIs) and uses thereof
JP6830895B2 (ja) ストレス誘発性ｐ−ｔａｕを低下させるトリアゾロピリジン及びトリアゾロピリミジン
WO2016028910A1 (en) Apoe4-targeted theraputics that increase sirt1